An Invitation to Support Cancer Immunotherapy Research

Cancer therapy has continually advanced, allowing many cancer patients to return to years of a normal and healthy lifestyle. Yet, cancer was still the second leading cause of death in 2018, according to the World Health Organization (WHO), with nearly one in six deaths per year being attributed to some form of cancer.

While chemotherapies targeting specific genetic mutations are gradually emerging, cancer therapy has received a substantial boost through immunotherapy, led by anti-PD-1 antibody therapy. The success of such immunotherapy strategies has been clinically demonstrated in patients who had previously experienced cancer recurrence or had been unresponsive to chemotherapies.

Despite the proof of concept of cancer immunotherapy, the field still has many challenges to address in order to deliver maximum benefit to the public. With the aim of realizing this goal, the Kyoto University Center for Cancer Immunotherapy and Immunobiology (CCII) was established on April 1st 2020 as the first Japanese research institute dedicated to addressing the multi-faceted challenges of cancer immunotherapy, aiming to lead the world in advancing state-of-the-art therapies for cancer patients. Research at CCII integrates the cutting edge of medical knowledge and bioanalytical technologies to address unsolved clinical and basic science topics in cancer.

Achieving and maintaining such a world-class level of research, which translates to patient benefit at the bedside, requires substantial time and resources. This is where you or your organization can contribute and make an impact. Fiscal or equipment contributions will accelerate CCII’s research programs, empowering top scientists to work at high pace and rapidly drive forward new methods and knowledge for cancer immunotherapy. The advances enabled by your contributions will be disseminated in breaking reports and international symposia.

Together, we can change cancer from a frightful disease to a curable condition. I hope you will consider joining us in our drive for this humanitarian goal.

Sincerely yours,

Tasuku Honjo
Director
Center for Cancer Immunotherapy and Immunobiology
Kyoto University